Xencor (XNCR) News Today $8.69 -0.23 (-2.58%) Closing price 04:00 PM EasternExtended Trading$8.68 0.00 (-0.06%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Barclays Keeps Their Sell Rating on Xencor (XNCR)April 3 at 7:01 PM | markets.businessinsider.comXencor (NASDAQ:XNCR) Trading Down 7.4% - Here's What HappenedXencor (NASDAQ:XNCR) Trading Down 7.4% - Should You Sell?April 3 at 3:56 PM | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week Low - Should You Sell?Xencor (NASDAQ:XNCR) Hits New 12-Month Low - Time to Sell?April 1 at 3:06 PM | marketbeat.comRaymond James Financial Inc. Acquires New Holdings in Xencor, Inc. (NASDAQ:XNCR)Raymond James Financial Inc. bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 101,346 shares of the biopharmaceutical company's stock, valued at approxMarch 30, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Shares Acquired by Loomis Sayles & Co. L PLoomis Sayles & Co. L P increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,092,346 shares of the biopharmaceutical company's stock after buying an additMarch 29, 2025 | marketbeat.comAnalysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.38March 28, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Stock Price Down 5.3% - Here's WhyXencor (NASDAQ:XNCR) Trading Down 5.3% - Should You Sell?March 27, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Hits New 12-Month Low - Here's What HappenedXencor (NASDAQ:XNCR) Reaches New 1-Year Low - Should You Sell?March 26, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from BrokeragesXencor, Inc. (NASDAQ:XNCR - Get Free Report) has received a consensus rating of "Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the companyMarch 25, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 3.9% Higher - Here's WhyXencor (NASDAQ:XNCR) Trading Up 3.9% - What's Next?March 21, 2025 | marketbeat.comAmundi Acquires 24,494 Shares of Xencor, Inc. (NASDAQ:XNCR)Amundi increased its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 225.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,380 shares of the biopharmaceutical company's stock afteMarch 20, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Reaches New 12-Month Low - What's Next?Xencor (NASDAQ:XNCR) Sets New 52-Week Low - Here's What HappenedMarch 18, 2025 | marketbeat.comPrimecap Management Co. CA Decreases Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)Primecap Management Co. CA trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,984,432 shares of the biopharmaceuticaMarch 18, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday.March 14, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 52-Week Low - Here's What HappenedXencor (NASDAQ:XNCR) Hits New 1-Year Low - Should You Sell?March 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Upgraded by StockNews.com to "Hold" RatingStockNews.com upgraded shares of Xencor from a "sell" rating to a "hold" rating in a report on Thursday.March 6, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Sets New 1-Year Low - Here's WhyXencor (NASDAQ:XNCR) Hits New 12-Month Low - What's Next?March 5, 2025 | marketbeat.comPrincipal Financial Group Inc. Grows Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)Principal Financial Group Inc. grew its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 16.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 340,145 shares of the biopharmaceutical companyMarch 2, 2025 | marketbeat.comBarclays Reaffirms Their Sell Rating on Xencor (XNCR)March 1, 2025 | markets.businessinsider.comWells Fargo & Company Cuts Xencor (NASDAQ:XNCR) Price Target to $33.00Wells Fargo & Company reduced their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday.March 1, 2025 | marketbeat.comXencor price target lowered to $32 from $34 at RBC CapitalMarch 1, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Stake Raised by Rhumbline AdvisersRhumbline Advisers increased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,000 shares of the bioMarch 1, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Posts Quarterly Earnings ResultsXencor (NASDAQ:XNCR - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%.February 28, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 7.8% Higher on Better-Than-Expected EarningsXencor (NASDAQ:XNCR) Stock Price Up 7.8% Following Earnings BeatFebruary 28, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Xencor (XNCR) and Merus (MRUS)February 28, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned aFebruary 28, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Downgraded by StockNews.com to "Sell"StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a report on Wednesday.February 28, 2025 | marketbeat.comXencor reports Q4 EPS ( 62c), consensus (78c)February 27, 2025 | markets.businessinsider.comXencor sees ending FY25 with $535M -$585M in cashFebruary 27, 2025 | markets.businessinsider.comXencor Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | businesswire.comXencor (NASDAQ:XNCR) Hits New 1-Year Low - Here's WhyXencor (NASDAQ:XNCR) Sets New 12-Month Low - Here's WhyFebruary 24, 2025 | marketbeat.comXencor (XNCR) to Release Quarterly Earnings on TuesdayXencor (NASDAQ:XNCR) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comXencor reports financial restatements, cites errorsFebruary 13, 2025 | msn.comEssex LLC Sells 19,000 Shares of Xencor, Inc. (NASDAQ:XNCR)Essex LLC decreased its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,661 shares of the biopharmaceutical company's stock after selling 19,000 shares during the quarter. EssexFebruary 9, 2025 | marketbeat.comXencor's SWOT analysis: biotech stock faces mixed outlook amid pipeline progressFebruary 5, 2025 | msn.comXencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past weekFebruary 1, 2025 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Short Interest Up 21.4% in JanuaryXencor, Inc. (NASDAQ:XNCR - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 4,990,000 shares, an increase of 21.4% from the December 31st total of 4,110,000 shares. Based on an average daily volume of 603,100 shares, the days-to-cover ratio is presently 8.3 days.February 1, 2025 | marketbeat.comXencor: Substantial Promise, Slow ProgressJanuary 30, 2025 | seekingalpha.comXencor (NASDAQ:XNCR) Stock Price Down 3.9% - Time to Sell?Xencor (NASDAQ:XNCR) Shares Down 3.9% - Time to Sell?January 24, 2025 | marketbeat.comXencor's SWOT analysis: biotech stock navigates pipeline progress amid market challengesJanuary 23, 2025 | msn.comXencor (NASDAQ:XNCR) Trading Down 3.8% - Should You Sell?Xencor (NASDAQ:XNCR) Shares Down 3.8% - Should You Sell?January 17, 2025 | marketbeat.comBank of America Securities Remains a Buy on Xencor (XNCR)January 14, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)January 14, 2025 | markets.businessinsider.comXencor (NASDAQ:XNCR) Stock Price Down 9.3% - Should You Sell?Xencor (NASDAQ:XNCR) Trading Down 9.3% - Here's WhyJanuary 10, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by BrokeragesShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Buy" from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy ratingJanuary 9, 2025 | marketbeat.com26,831 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Sanctuary Advisors LLCSanctuary Advisors LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 26,831 shares of the biopharmaceutical company's stock, valued at approximately $540,000. Other inDecember 26, 2024 | marketbeat.comBarclays PLC Raises Stake in Xencor, Inc. (NASDAQ:XNCR)Barclays PLC raised its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 100.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 155,568 shares of the biopharmaceutical company's stock after acquiring an addiDecember 24, 2024 | marketbeat.comJane Street Group LLC Has $3.39 Million Stake in Xencor, Inc. (NASDAQ:XNCR)Jane Street Group LLC grew its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 18.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,431 shares of the biopharmaceutical company's stock after acquiring an addiDecember 20, 2024 | marketbeat.comState Street Corp Reduces Stake in Xencor, Inc. (NASDAQ:XNCR)State Street Corp cut its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,119,290 shares of the biopharmaceutical company's stock after selling 233,086 sharDecember 19, 2024 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Buy" by AnalystsShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationDecember 15, 2024 | marketbeat.com Remove Ads Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Media Mentions By Week XNCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XNCR News Sentiment▼0.410.61▲Average Medical News Sentiment XNCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XNCR Articles This Week▼53▲XNCR Articles Average Week Remove Ads Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Protagonist Therapeutics News Catalyst Pharmaceuticals News Alvotech News Merus News Immunovant News Metsera News MorphoSys News ACADIA Pharmaceuticals News Apellis Pharmaceuticals News Viking Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XNCR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XNCR Stock Free XNCR Stock Alerts